TNF and rheumatoid arthritis: In 2022, the Oral Rheumatoid Arthritis Trial (ORAL surveillance study) found a higher risk of major adverse cardiovascular events and venous thromboembolic events in patients with RA and cardiovascular risk factors treated with Tofacitinib than with TNF inhibitors [37].